Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cardiff Oncology (CRDF) Cost of Revenue (2016 - 2018)

Cardiff Oncology's Cost of Revenue history spans 6 years, with the latest figure at $26677.0 for Q3 2018.

  • For Q3 2018, Cost of Revenue fell 94.36% year-over-year to $26677.0; the TTM value through Jun 2019 reached $26677.0, down 98.13%, while the annual FY2018 figure was $597457.0, 67.02% down from the prior year.
  • Cost of Revenue for Q3 2018 was $26677.0 at Cardiff Oncology, down from $204436.0 in the prior quarter.
  • Across five years, Cost of Revenue topped out at $3.1 million in Q2 2016 and bottomed at -$1.7 million in Q4 2014.
  • The 5-year median for Cost of Revenue is $521396.0 (2014), against an average of $898442.0.
  • The largest annual shift saw Cost of Revenue plummeted 550.41% in 2014 before it soared 1594.66% in 2016.
  • A 5-year view of Cost of Revenue shows it stood at -$1.7 million in 2014, then surged by 110.3% to $173537.0 in 2015, then soared by 1280.51% to $2.4 million in 2016, then plummeted by 83.99% to $383593.0 in 2017, then plummeted by 93.05% to $26677.0 in 2018.
  • Per Business Quant, the three most recent readings for CRDF's Cost of Revenue are $26677.0 (Q3 2018), $204436.0 (Q2 2018), and $366344.0 (Q1 2018).